4 Healthcare Stock Stories Getting Noticed on Monday
Merck & Co. (NYSE:MRK): Closing price $45.40
A type of HIV medicine that stops the AIDS virus from entering immune system cells might in the future be employed against cancer in new combination therapies being developed by drug firms. Industry analysts at Citi think that Merck is poised to take the situation to the next phase by testing its CCR5 drug vicriviroc in cancer patients. The product had been abandoned as a treatment for HIV in 2010 after an unsuccessful study.